SCHEMBL477070

SCHEMBL477070

C[C@@H]1CN(c2ccc3nc(C4CC4)c(-c4ccnc(Cl)c4)n3n2)CCN1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CSNK1E P49674 7/20 0.54
PRKD1 Q15139 2/20 0.37
PRKD2 Q9BZL6 2/20 0.37
PRKCQ Q04759 1/20 0.36
PRKCD Q05655 1/20 0.36
NMT1 P30419 1/20 0.36
ACVR1 Q04771 2/20 0.35
ZAP70 P43403 3/20 0.35
FGFR1 P11362 1/20 0.35
KIT P10721 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAPK13 O15264 1/20 0.34
MAPK12 P53778 1/20 0.34
MAPK11 Q15759 1/20 0.34
MAPK14 Q16539 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL477068 1.00 CSNK1E (0.54) CSNK1EPRKD1PRKD2PRKCQPRKCD
SCHEMBL477111 0.90 CSNK1E (0.55) CSNK1EPRKD1PRKD2PRKCQPRKCD
SCHEMBL477110 0.90 CSNK1E (0.55) CSNK1EPRKD1PRKD2PRKCQPRKCD
SCHEMBL477136 0.89 CSNK1E (0.54) CSNK1EPRKD1PRKD2PRKCQPRKCD
SCHEMBL477135 0.89 CSNK1E (0.54) CSNK1EPRKD1PRKD2PRKCQPRKCD
SCHEMBL477114 0.88 CSNK1E (0.51) CSNK1EPRKD1PRKD2PRKCDNMT1
SCHEMBL477073 0.87 CSNK1E (0.52) CSNK1EPRKD1PRKD2PRKCQPRKCD
SCHEMBL477074 0.87 CSNK1E (0.52) CSNK1EPRKD1PRKD2PRKCQPRKCD
SCHEMBL477054 0.86 CSNK1E (0.70) CSNK1EKITMAPK13MAPK12MAPK11
SCHEMBL477055 0.86 CSNK1E (0.70) CSNK1EKITMAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2331546-B1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI SA (FR) 2012-02-01 EP claimed
US-20110312934-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2011-12-22 US claimed
EP-2331546-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF Sanofi-aventis (FR) 2011-06-15 EP claimed
WO-2010018327-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2010-02-18 WO claimed
EP-2331546-B1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI SA (FR) 2012-02-01 EP disclosed
US-20110312934-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312934-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF NR3C1, CNKSR1, NR3C2 CSNK1E 2760/4885PRKD1 4214/4885PRKD2 3046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.